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Gain-of-function mutations in with no lysine (K) 1 (WNK1) and WNK4 genes are responsible for familial hyperkalemic
hypertension (FHHt), a rare, inherited disorder characterized by arterial hypertension and hyperkalemia with metabolic
acidosis. More recently, FHHt-causing mutations in the Kelch-like 3–Cullin 3 (KLHL3-CUL3) E3 ubiquitin ligase complex
have shed light on the importance of WNK’s cellular degradation on renal ion transport. Using full exome sequencing for a
4-generation family and then targeted sequencing in other suspected cases, we have identified new missense variants in
the WNK1 gene clustering in the short conserved acidic motif known to interact with the KLHL3-CUL3 ubiquitin complex.
Affected subjects had an early onset of a hyperkalemic hyperchloremic phenotype, but normal blood pressure
values”Functional experiments in Xenopus laevis oocytes and HEK293T cells demonstrated that these mutations strongly
decrease the ubiquitination of the kidney-specific isoform KS-WNK1 by the KLHL3-CUL3 complex rather than the long
ubiquitous catalytically active L-WNK1 isoform. A corresponding CRISPR/Cas9 engineered mouse model recapitulated
both the clinical and biological phenotypes. Renal investigations showed increased activation of the Ste20 proline
alanine–rich kinase–Na+-Cl– cotransporter (SPAK-NCC) phosphorylation cascade, associated with impaired ROMK apical
expression in the distal part of the renal tubule. Together, these new WNK1 genetic variants highlight the importance of
the KS-WNK1 isoform abundance on potassium homeostasis.
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Introduction
Familial hyperkalemic hypertension (FHHt), also known as Gor-
don syndrome and pseudohypoaldosteronism type 2, is a rare dis-
ease associated with net positive Na+ balance and renal K+ retention 
resulting in hypertension, hyperkalemia, and hyperchloremic meta-
bolic acidosis (1). Mutations causing FHHt were first identified in the 
WNK1 and WNK4 genes that encode 2 members of the with no lysine 
(K) (WNK) serine-threonine kinase family (2). More recently, we and 
others have identified disease-causing mutations in the Kelch-like 3 
(KLHL3) and Cullin 3 (CUL3) proteins belonging to a ubiquitin-pro-
tein ligase complex (3, 4). This complex has been shown in vitro to 
interact with WNK1 and WNK4, induce their ubiquitination, and 
regulate their protein levels through proteasomal degradation (5–8). 
Ohta and collaborators mapped the interaction site in WNK1 to a 
region containing a short acidic motif, which is highly conserved 
among the members of the WNK family (5). Interestingly, most 
of the FHHt-causing WNK4 variants cluster in this motif and are 
charge changing. WNK4 proteins carrying the same mutations fail 
to interact with the KLHL3 adaptor protein in vitro (5–7). This causes 
increased WNK4 abundance with secondary activation of the Na+-
Cl– cotransporter (NCC) and development of FHHt (6, 7).
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lemia, but with normal BP) and 6 unaffected individuals (Figure 
1A and Supplemental Table 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI94171DS1). 
Using a SNP-based linkage approach, 7 suggestive linkage regions 
(maximum logarithm of odds [LOD] score = 1.8 in all linked 
regions) were identified in this panel (Supplemental Table 1B). In 
total, linked regions spanned 69 Mb and included 829 protein-cod-
ing genes. After filtering, WES performed in 1 unaffected and 2 
affected individuals identified 71 possible disease-causing coding 
variants (Supplemental Table 1C). Four missense variants mapped 
to the linkage regions and were predicted in silico to be damaging. 
These variants were located in solute carrier family 30 member 7, 
a zinc transporter (SLC30A7), kinesin family member 11 (KIF11), 
tectonic family member 3 (TCTN3), and WNK1. The WNK1 vari-
ant (c.1905T>A; P.Asp635Glu) (Figure 1B) was located in exon 7 
(ex7), which encodes the conserved acidic motif, previously shown 
to mediate the interaction with the substrate adaptor KLHL3 (14).
Additional variants in the WNK1 acidic motif in other cases and kin-
dreds. FHHt-causing WNK4 mutations are located in ex7 and ex17, 
encoding highly conserved acid and base motifs, respectively. Thus, 
we screened the homologous motifs of WNK1 encoded by ex7 and 
ex25, respectively, in 26 unrelated affected cases previously found 
as negative for the classical mutations in WNK4, KLHL3, CUL3, or 
the intron 1 deletion in WNK1. Direct sequencing identified 5 addi-
tional nonsynonymous heterozygous variants in ex7 in 8 unrelated 
subjects (Figure 2, A–C). The in silico pathogenicity of these variants 
is described in Supplemental Table 2. All were located within the 
acidic motif, between positions 631 and 636 of the L-WNK1 protein, 
and were predicted to be pathogenic. Four of the 6 missense variants 
were charge changing (E631K, D635N, Q636R, Q636E); 2 affected 
residues (D635, Q636) were also found mutated in the homologous 
acidic motif of WNK4 (D564 and Q565, Figure 2, C and D)
Clinical and biochemical characteristics: hydrochlorothiazide-sen-
sitive hyperkalemic acidosis without hypertension. Detailed clinical 
and biological characteristics of index cases are given in Table 1. 
The circumstances of discovery and the clinical symptoms of these 
index patients are detailed in Supplemental Table 3. In most of the 
cases, patients were asymptomatic and showed with no signs of 
hyperkalemia on an electrocardiogram. All displayed the electro-
lyte anomalies typical of FHHt, including marked hyperkalemia 
(median, 5.9 mmol/L; IQR, 5.3–6.3), hyperchloremia (median, 
108 mmol/L; IQR, 106–110), and metabolic acidosis (total CO2, 
20 mmol/L; IQR, 19–21) despite a normal glomerular filtration rate 
(GFR) (median creatinine, 58 μmol/L; IQR, 47–74). For the 7 index 
cases with prospective reliable clinical data, hyperkalemia and 
hyperchloremia were rapidly corrected with low doses of hydro-
chlorothiazide (HCTZ) (6.25 to 25 mg/d; Supplemental Figure 1). In 
comparison, an average drop in potassium of only 0.7 mmol/L was 
observed in normal, healthy subjects administered a much higher 
dose of HCTZ (50 mg for 3 weeks) (15). Compared with reference 
values (16), we also observed a tendency for significant hypercalci-
uria in infancy and adulthood (Supplemental Figure 2).
Surprisingly, most of the index cases had casual BP values in 
the normal range, except a 25-year old woman with associated 
obesity (K3-1, BMI, 32 kg/m2) and a 22-year old woman (K88-1) 
without other cardiovascular risk factors, but who had short stature 
and mild mental retardation (Table 1). This tendency for normal 
The genetic heterogeneity of FHHt is reflected in its phe-
notypic heterogeneity, ranging from severe cases presenting in 
childhood to mild and sometimes asymptomatic cases presenting 
in late adulthood (9, 10). A similar spectrum exists for the more 
recent causal genes KLHL3 and CUL3, with CUL3 mutations caus-
ing the most severe hypertension and electrolyte abnormalities (3). 
A milder phenotype was suggested for the WNK1-FHHt cases that 
could be partly explained by a different mutational mechanism. 
Indeed, the WNK1 gene gives rise to 2 main isoforms: a long ubiq-
uitously expressed and catalytically active isoform (L-WNK1) and 
a short kidney-specific isoform (KS-WNK1) that is only expressed 
in the distal nephron (11, 12). FHHt-causing WNK1 mutations 
were found to be large deletions located in intron 1, resulting in an 
increased expression of L-WNK1 in the distal convoluted tubule 
(DCT) and connecting tubule (CNT) (13).
We have now identified cases and families with inherited 
hyperkalemic hyperchloremic acidosis carrying missense variants 
in the WNK1 gene that all cluster in the conserved acidic motif and 
are similar to those found previously in WNK4. Affected subjects 
had a clear electrolyte phenotype, but no significant blood pres-
sure (BP) increase, especially in comparison with those who had 
similar WNK4 mutations. Their functionality was tested in Xeno-
pus laevis oocytes and HEK293T cells, showing that they mainly 
affect the regulation of KS-WNK1 by the KLHL3-CUL3 ubiqui-
tin complex. Using the CRISPR/Cas 9 genome-editing system, a 
mouse line was created that replicated the human phenotype and 
that was used to analyze the consequences of mutations at the 
WNK1 acidic motif on renal transport.
Results
A missense variant in the WNK1 acidic motif in the first FHHt kindred. 
We took advantage of one 4-generation family to combine linkage 
analysis and whole exome sequencing (WES). This family includ-
ed 7 affected individuals (all with metabolic acidosis and hyperka-
Figure 1. Missense variant in the WNK1 acidic motif in the FHHt pedigree 
29. (A) Kindred 29: family affected by FHHt composed of 7 affected (black) 
and 6 unaffected (white) members. Arrow indicates the index case. Aster-
isks indicate exome-sequenced individuals. (B) Electrophoregram obtained 
by Sanger sequencing showing the double-peak A/T corresponding to the 
WNK1 heterozygous mutation (c.1905T>A; P.Asp635Glu). 
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only); BP was much higher in patients with WNK4 mutations (SBP 
and DBP averaged ~20 mmHg and ~10 mmHg higher) compared 
with that in patients with WNK1 ex7 mutations.
The WNK1 ex7 mutations selectively abolish the ubiquitination 
and degradation of the KS-WNK1 isoform in vitro. The acidic motif 
common to WNK1 and WNK4 has been reported as a binding site 
for the CUL3 and KLHL3 E3-ubiquitin ligase complex (14). There-
fore, we tested the effect of KLHL3 on the abundance of WT and 
mutant L- and KS-WNK1 isoforms (Figure 3). The expression of 
KLHL3 in X. laevis oocytes resulted in a small (about 30%), but 
significant, decrease in the amount of L-WNK1 and almost com-
pletely abolished KS-WNK1. We then analyzed the recurrent 
WNK1 A634T variant, found in the K58 and K75 kindreds. No sig-
nificant change in L-WNK1 abundance was observed between the 
WT and mutant isoforms, whereas the KS-WNK1-A227T mutant 
BP values was confirmed in the first-degree relatives harboring 
the familial mutations, since only 2/10 were mildly hypertensive 
(Supplemental Table 4). Overall, the 20 mutated individuals with 
measured BP (23 ± 18 years) belonging to 9 affected families had 
normal systolic BP (SBP) (116 ± 20 mmHg) and diastolic BP (DBP) 
(73 ± 21 mmHg). Low or suppressed plasma renin levels were 
observed with normal to slightly elevated plasma aldosterone 
concentrations (Table 1 and Supplemental Table 4), as has been 
observed with other FHHt genotypes.
We then compared the clinical phenotypes of FHHt patients 
with WNK1 ex7 missense mutations with those who had WNK4 
missense variants affecting the same acidic motif collected in our 
center and in the literature (Table 2). Interestingly, WNK4-related 
patients consistently had the strongest BP and electrolyte pheno-
type, whatever the subclassification (index cases, adults or males 
Figure 2. Acidic motif WNK1 mutations. (A) Schematic representation of the WNK1 gene. The coordinates of the different exons are indicated above or 
below the structure with ex7 and ex25 (gray), which code for the conserved acidic and basic motifs. The proximal promoter (pP) drives the expression of 
the long ubiquitous kinase active isoform (L-WNK1), whereas the renal promoter (rP) drives the expression of the kinase defective kidney-specific isoform 
(KS-WNK1). (B) Schematic linear structure of LWNK1 and KS-WNK1. The kinase domain is represented in full black, the autoinhibitory domain (AID) is 
striped, coiled-coil domain 1 (CC1) and CC2 are represented in gray, and the conserved acidic motif (AM) and basic motif (BM) are represented in red. (C) 
Location and sequences of the mutated residues clustering in the acidic motif. The brackets indicate the number of unrelated affected subjects for each 
mutation. On the lower right are shown the Sanger sequencing electrophoregrams showing the various missense WNK1 mutations. (D) Conservation of 
the acidic motif showing residues mutated in FHHt among human WNK family members. The previously described WNK4 mutations are indicated in red; 
those at WNK1 and identified in this study in blue. All are located at completely conserved residues. The bottom part shows the conservation of the WNK1 
acidic motif across species. The mutated residues are indicated in bold.
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was highly expressed in comparison with the WT KS-WNK1 iso-
form, suggesting that the mutation abrogates the degradation of 
KS-WNK1 (Figure 3A). We also tested the other observed WNK1 
missense variants of the acidic motif using the same experimental 
system (Supplemental Figure 3A). All were protective with regard 
to KLHL3/CUL3-mediated degradation.
Since both WNK1 isoforms are physiologically coexpressed 
in the distal nephron (12), we sought to characterize how KLHL3/
CUL3-mediated degradation affects KS- and L-WNK1 abundance 
in coexpression experiments (Figure 3B). On KLHL3 expression, 
a 70%–80% decrease in WT KS-WNK1 abundance was observed, 
while there was no change in L-WNK1. This major difference was 
not observed after transfection with the mutated isoforms. The coex-
pression of WT and mutant isoforms led to an intermediate decrease 
in KS-WNK1 abundance, suggesting that only the WT KS-WNK1 was 
degraded. Overall, these results suggest that human mutations of the 
WNK1 acidic motif selectively increase KS-WNK1 abundance in the 
distal nephron where KLHL3 is exclusively expressed.
We also tested the effect of KLHL3 on the WT and mutant 
WNK1 isoforms in human tissue culture HEK293T cells. Since we 
found that this cell line expresses high levels of CUL3, but unde-
tectable levels of KLHL3, we first established a stable tetracycline- 
inducible cell line expressing KLHL3 (see Supplemental Methods). 
The induction of KLHL3 resulted in a dramatic decrease in the 
level of transfected KS-WNK1, but not L-WNK1 (Figure 4A). The 
introduction of the D635N mutation (D228N for the KS-WNK1 
isoform) prevented this decrease. Interestingly, all other muta-
tions were also protective with regard to KLHL3/CUL3-mediated 
degradation, with the exception of KS-WNK1 D228E (Supplemen-
tal Figure 3B). The substitution of an aspartic acid (D) by a glutam-
ic acid (E) was not charge changing, which might explain the mild-
er phenotype. The coexpression of L- and KS-WNK1 in HEK293T 
cells confirm the observations made in Xenopus oocytes (Figure 
4B). Next, we immunoprecipitated L- and KS-WNK1 and assayed 
their ubiquitination status in denaturing conditions to exclude any 
ubiquitination signal linked to WNK1 interactors. KLHL3 induc-
tion resulted in heavy KS-WNK1 ubiquitination, whereas it had 
little or no effect on L-WNK1 or D635N (D228N) mutants (Fig-
ure 4C). KS-WNK1 ubiquitination by the KLHL3/CUL3 complex 
suggests that the E3 ligase adaptor (KLHL3) and the substrate 
(WNK1) interact. Indeed, both L-WNK1 and KS-WNK1 coimmu-
noprecipitated KLHL3 in native conditions. However, KS-WNK1 
did so with a much higher efficiency (Figure 4D). As expected, 
the D635N mutation in the acidic domain (D228N in KS-WNK1) 
reduced the interaction with KLHL3. Taken together, our in vitro 
studies strongly suggest that KS-WNK1 is the preferential WNK1 
isoform target of the KLHL3/CUL3 ubiquitin complex and that the 
mutations identified in WNK1 ex7 prevent this ubiquitination.
A mouse model bearing a mutation at the WNK1 acidic motif con-
firms the absence of arterial hypertension despite a typical electrolyte 
phenotype. To understand why WNK1 ex7 missense mutations lead 
to a hyperkalemic metabolic acidosis with normal BP in most of 
the affected patients, we sought to generate a mouse model bear-
ing the D635E mutation at the WNK1 acidic motif using CRISPR/
Cas9 genome-editing technology (Supplemental Figure 4A). The 
knockin of the point mutation was not found in 300 microinject-
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to the deletion of the first amino acid of the WNK1 acidic motif 
(delE631) was observed in 7/300 injected oocytes (Supplemen-
tal Figure 4B). In vitro, this mutant had an effect similar to that 
of the reference D635N variant, abrogating the KLHL3-induced 
decrease in KS-WNK1 abundance (Supplemental Figure 4C). The 
analysis of the BP and plasma electrolyte concentration confirmed 
that the heterozygous Wnk1+/delE631 mice represent an adequate 
model in which to study the in vivo consequences of the WNK1 
mutations identified in our patients.
Using telemetry, we found that basal SBP and DBP were sim-
ilar in heterozygous Wnk1+/delE631 mice and WT littermates (Figure 
5A) as well as on HCTZ (Figure 5B). Tail-cuff measured SBP on 
a larger set of adult males also revealed the absence of hyper-
tension (113 ± 5 mmHg, n = 20 Wnk1+/delE631 vs. 108 ± 5 mmHg, 
n = 20 Wnk1+/+, NS). The homozygous Wnk1delE631/delE631 mice were 
perfectly viable, with no departure from the expected Mendelian 
proportions when heterozygous mice were crossed. The biological 
phenotype of these homozygous mice did not differ from that the 
heterozygous mice, with the exception of SBP, which was signifi-
cantly higher than in heterozygous or WT littermates when mea-
sured by tail cuff (Supplemental Table 5). We focused our studies 
on the heterozygous model, since it corresponds to the human 
autosomal dominant pathology.
Wnk1+/delE631 mice displayed hyperkalemia (5.1 ± 0.5 mmol/L) 
and hyperchloremia (114 ± 2 mmol/L) (Figure 5, D–F) that were 
corrected by 3-day HCTZ oral administration (Table 3). Urinary 
aldosterone excretion was increased 2-fold, whereas renin expres-
sion was decreased by 45% in Wnk1+/delE631 mice (Figure 5G, Table 
3 and Supplemental Table 6). This difference remained significant 
after a 7-day low K+ diet and normalization of kalemia (Figure 5H), 
suggesting that the lower renin was probably the consequence of 
a mild volume expansion rather than the hyperkalemic state (17). 
To better appreciate the absence of hypertension in this model, we 
performed BP telemetry measurements in Wnk1+/delE631 and Wnk1+/+ 
male littermates (6 to 7 months old) on a 1-week normal standard 
diet (0.3% NaCl) followed by a 1-week high NaCl (3%) diet (Figure 
5C). The results confirm that there were no differences in basal 
BP between the 2 groups (SBP, 124.5 ± 10.4 in Wnk1+/+ vs. 125.2 ± 
8.4 mmHg in Wnk1+/delE631) as well as no significant BP increase on 
a high-sodium diet (SBP: 120.6 ± 10.1 in Wnk1+/+ vs. 128.1 ± 10.1 
mmHg in Wnk1+/delE631; Supplemental Table 6).
Increased activation of the SPAK-NCC phosphorylation cascade. 
The extreme sensitivity of FHHt patients to thiazide diuretics 
initially suggested that the syndrome resulted from an increased 
activity of the Na+-Cl– cotransporter NCC. This hypothesis was 
confirmed by the demonstration that NCC abundance and phos-
phorylation are increased in all FHHt mouse hypertensive mod-
els (13, 18–20). Despite the absence of arterial hypertension, we 
observed the same phenomenon in the renal cortex of Wnk1+/delE631 
mice compared with Wnk1+/+ littermates (Figure 6). The Ste20 pro-
line alanine rich kinase (SPAK) kinase is essential for the expres-
sion and phosphorylation of NCC in vivo (20, 21). Immunoblotting 
on whole-kidney cortex homogenates showed that SPAK phos-
phorylation was greater in Wnk1+/delE631 mice compared with Wnk1+/+ 
(Figure 6). We also observed an increased abundance of the full-
length SPAK isoform, which is the one predominantly expressed in 
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dative stress–responsive kinase 1 (OSR1). WNK4 abundance was 
not significantly changed in the kidney of Wnk1+/delE631 mice (Fig-
ure 6). However, due to the lack of a suitable antibody, we could 
not measure the phosphorylation level of the T-loop serine, which 
reflects the activation state of the kinase (23).
To further characterize the activation of the WNK1-SPAK/
OSR1 cascade in the kidney of Wnk1+/delE631 mice, we performed 
immunofluorescence experiments with an antibody recognizing 
both L- and KS-WNK1 isoforms (a KS-WNK1–specific antibody 
was not available). While the DCT of Wnk1+/+ mice contained 
small WNK1-positive puncta, large WNK1-positive structures, 
resembling the previously described WNK bodies, were observed 
in Wnk1+/delE631 NCC-positive DCTs (Figure 7). These bodies were 
also found in some AQP2-positive, but not in NKCC2-positive, 
tubules. Previous studies demonstrated that KS-WNK1 is required 
for the formation of these WNK1 bodies, which are dynamic 
membraneless structures (24). Containing the components of the 
WNK/SPAK pathway, they are usually not present at baseline con-
ditions, but form under conditions of low potassium intake when 
WNKs become activated (25). The fact that we observed them at 
baseline in Wnk1+/delE631 kidneys provides further support that the 
WNK1/SPAK cascade is activated in Wnk1+/delE631 mice.
Potassium secretory capacity is diminished without change of 
ENaC expression in Wnk1+/delE631 mice. Basal urinary K+ excretion and 
urinary/plasma ratio of K+ concentration were lower in Wnk1+/delE631 
mice, indicating a defect in urinary potassium excretion (Figure 8, A 
and B). We calculated the transtubular potassium gradient (TTKG) 
to estimate the potassium secretory capacity of the aldosterone 
sensitive distal nephron (ASDN), connective tubule and collecting 
duct (26). Wnk1+/delE631 mice exhibited significantly lower TTKG (8.6 
± 0.3, n = 24) than Wnk1+/+ mice (10.1 ± 0.3, n = 24, P = 0.0003), 
despite higher aldosterone levels, consistent with a potassium 
secretory defect (Figure 8C). As observed in patients, HCTZ rap-
idly corrected the hyperkalemia in the Wnk1+/delE631 mice (see above) 
and partially abolished the TTKG difference between the Wnk1+/+ 
and Wnk1+/delE631 mice (Figure 8C), suggesting the defect develops as 
a consequence of increased Na+ reabsorption by NCC and reduced 
sodium delivery to ASDN. Metolazone, a thiazide diuretic suggest-
ed as having less carbonic anhydrase inhibitory effect, did not cor-
rect the phenotype when administered intraperitoneally at a dose 
of 50 μg/kg/d over 4 days (Supplemental Figure 5).
Decreased activity of the epithelial sodium (Na) Channel ENaC 
and the renal outer medullary potassium (K) channel ROMK are 
thought to contribute to the hyperkalemia in other forms of FHHt 
Figure 3. Differential effect of the WNK1 Ex7 G1900A (A634T-L-WNK1; A227T-KS-WNK1) variant on the interaction between KLHL3 and L-WNK1 or 
KS-WNK1 isoforms. (A) Representative immunoblot of proteins extracted from X. laevis oocytes (left panel) that were injected with WT or mutant L-WNK1 
or KS-WNK1 in the absence or presence of KLHL3 cRNA, as stated. The upper blot shows c-myc–positive bands corresponding to L-WNK1 and KS-WNK1. The 
middle blot shows unspecific upper band present in all lanes (*), including water-injected oocytes, and a lower band corresponding to KLHL3 only present in 
KLHL3-injected oocytes. The lower blot shows actin. Densitometry of several (n = 3) blots in which the effect of KLHL3 was tested in L-WNK1 or KS-WNK1 
WT or mutants separately (right panel). In the absence of KLHL3, mean values were arbitrarily set to 1.0, and in the presence of KLHL3, values were normal-
ized accordingly. *P < 0.05; **P < 0.01, unpaired Student’s t test. (B) Representative immunoblot of proteins extracted from X. laevis oocytes (left panel) 
that were injected with mixture of WT or mutant L-WNK1 and KS-WNK1 in the absence or presence of KLHL3 cRNA in order to analyze the consequences of 
L-WNK1 and KS-WNK1 coexpression. Immunoblot (left panel) and densitometry analysis of several blots (right panel) are as in Figure 3A.
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(27). Abundance of ENaC α and γ subunits in the membrane-en-
riched fraction of the renal cortex was assessed as a surrogate for 
channel function (28, 29). No significant increases in the abundance 
in full-length or cleaved forms of the ENaC subunits were observed 
in Wnk1+/delE631 mice compared with Wnk1+/+, except for the short frag-
ment of α subunit (Figure 8D). We then acutely treated Wnk1+/delE631 
and Wnk1+/+ mice with amiloride, the specific pharmacological inhib-
itor of ENaC. Six hours after the amiloride injection, the natriuresis 
increased very significantly and similarly in both groups that had sim-
ilar Na and K intake (Figure 8E). Urinary K+ excretion also decreased 
similarly in Wnk1+/+ and in Wnk1+/delE631 (Figure 8F), the difference in 
postamiloride absolute values reflecting the difference in basal val-
ues. Together, these results make it seem unlikely that alterations in 
ENaC contribute to the potassium secretory defect.
Altered regulation of ROMK in Wnk1+/delE631 mice. We then analyzed 
ROMK expression in the kidney cortex and at the apical pole of the 
Figure 4. KLHL3 interaction with WNK1 isoforms in HEK293T cells: KLHL3 ubiquitinates KS-WNK1 and significantly reduces its protein levels. (A) 
Flp-In T-Rex 293 cells stably and inducibly expressing (His)6-protein C-Flag-hKLHL3 were transfected with myc-tagged L-WNK1 (WT or D635N mutant) or 
KS-WNK1 (WT or D228N mutant), as indicated. At 34 hours after transfection, cells were induced with tetracycline. Fourteen hours later (48 hours after 
transfection), cells were harvested and lysed in denaturing conditions. Cell lysates were subjected to immunoblot analysis with the indicated antibodies. 
Data shown are representative of 3 independent experiments. (B) Flp-In T-Rex 293 cells stably and inducibly expressing (His)6-protein C-Flag-hKLHL3 were 
transfected with ubiquitin-HA and myc-tagged L-WNK1, L-WNK1 D635N, KS-WNK1 or KS-WNK1 D228N, as indicated. At 34 hours after transfection, cells 
were induced with tetracycline. Fourteen hours later (48 hours after transfection), cells were harvested and lysed in denaturing conditions. Upper panel: 
Myc-tagged WNK1 isoforms were immunoprecipitated with anti-myc antibody (9B11, Cell Signaling Technology); immunoprecipitates were analyzed by 
immunoblotting with anti-HA antibody (3724S; Cell Signaling Technology). Nitrocellulose membranes were stripped and reblotted with anti-myc antibody. 
Immunoblot of cell lysates is represented in D (input). Data shown are representative of 3 independent experiments. (C) Cells were transfected with 
myc-tagged L-WNK1 (WT or D635N mutant) and KS-WNK1 (WT or D228N mutant), as indicated and in conditions similar to those in A. Cell lysates were 
subjected to immunoblot analysis with the indicated antibodies. Densitometric analysis was performed using FUJI FILM Multi-Gauge software. Results 
are shown as mean ± SEM. *P < 0.05 compared with control, unpaired Student’s t test. n = 3. (D) Flp-In T-Rex 293 cells stably and inducibly expressing 
(His)6-protein C-Flag-hKLHL3 were transfected with myc-tagged L-WNK1, L-WNK1 D635N, KS-WNK1, or KS-WNK1 D228N, as indicated. At 43 hours after 
transfection, cells were induced with tetracycline and simultaneously treated with MG132 for 5 hours. At 48 hours after transfection, cells were harvest-
ed and lysed in native conditions. Left panel: cell lysates were immunoprecipitated with anti-myc antibody, and immunoprecipitates were analyzed by 
immunoblotting with anti-protein C and anti-myc antibodies. Right panel: cell lysates (input) were subjected to immunoblot analysis with anti-myc and 
anti–protein C antibodies (HPC4, Roche) to check for even expression of KLHL3. Data shown are representative of 3 independent experiments.
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protein abundance of the Na-K-2Cl cotransporter (NKCC2) (Fig-
ure 9, C and D), which has been shown to be regulated in vivo by 
KS-WNK1 (31), was unchanged. In addition, a significant increase 
in NKCC2 phosphorylation was observed (Figure 9D) in accor-
dance with the observed increase in SPAK and OSR1, the main 
kinases involved in the phosphorylation of NKCC2 (32), and oppo-
site of the expected inhibitory effect KS-WNK1. We did not detect 
an increase in KS-WNK1 in NKCC2-positive tubules (Figure 7), 
suggesting that other regulatory mechanisms are at play (33).
Discussion
This is the first report, to our knowledge, of missense mutations 
in the WNK1 gene leading to an autosomal dominant tubulopa-
thy. The syndrome is striking in that it resembles more an isolat-
ed form of hyperkalemic renal distal tubular acidosis than a clas-
distal part of the DCT (DCT2) and CNT cells, where the channel 
is most significantly upregulated in response to dietary potassium 
loading (30). At the basal level, Western blots showed that ROMK 
protein expression was not increased in Wnk1+/delE631 mice compared 
with Wnk1+/+ littermates despite significant hyperkalemia (5.1 ± 0.1 
vs. 4.4 ± 0.1). In contrast, a significant increase in ROMK abundance 
was observed in WT mice when a similar rise in plasma potassium 
was induced by amiloride administration (Figure 9A). Immuno-
fluorescence experiments revealed that apical ROMK expression 
was not modified in either the DCT2 or  CNT of the hyperkalemic 
Wnk1+/delE631 mice compared with normokalemic Wnk1+/+ mice (Fig-
ure 9B). This lack of ROMK increase in the distal nephron is consid-
ered abnormal in these hyperkalemic Wnk1+/delE631 mice.
We also studied the large-conductance Ca++-activated K+ (BK) 
channel, the expression of which was unchanged. Likewise, the 
Figure 5. Normal BP on both normal and high-salt diet in Wnk1+/delE631 mice. (A–C) SBP and DBP profiles over 24 hours of SBP and DBP under a12-hour 
day/12-hour night schedule in Wnk1+/+ (n = 6) and Wnk1+/delE631 (n = 7) mice examined with a telemetric system under basal conditions (A). Night SBP and 
DBP of the same mice before (6 nights = basal) or during (7 nights) oral administration of HCTZ (240 mg/kg/d) (B). Night SBP and DBP of another group of 
mice (n = 4 Wnk1+/+, n = 4 Wnk1+/delE631) before (6 nights = basal) or during (6 nights) the administration of high (3%) Na+ diet (C). (D–F) Biological character-
istics. In the mutant mice, significant hyperkalemia (5.1 ± 0.5 vs. 4.3 ± 0.2 mmol/L, P < 0.0001; n = 20) (D); hyperchloremia (114 ± 2 vs. 110 ± 3 mmol/L,  
P < 0.0001; n = 20) (E); and metabolic acidosis (HCO3–, 22.8 ± 2.1 vs. 24.6 ± 2.5 mmol/L, P < 0.05; n = 20) (F) were observed together with normal creatinine 
values (not shown). Data are represented as mean ± SEM. Statistical comparisons were made using unpaired Student’s t test. (G and H) Renin expression. 
Levels of renin mRNA were measured by RT-qPCR in the kidney cortex of Wnk1+/+ (n = 7) and Wnk1+/delE631 (n = 7) mice in baseline conditions (G) or of Wnk1+/+ 
(n = 6) and Wnk1+/delE631 (n = 6) mice fed a low (0%) K+ diet (H). Results (mean ± SEM) are expressed in arbitrary units relative to the expression of ubc. The 
expression level in Wnk1+/+ mice under basal conditions was arbitrarily set to 1. *P< 0.05; **P < 0.01; ****P < 0.0001, unpaired Student’s t test.
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tested. Therefore, the potential difference in sensitivity of WNK1 
isoforms to KLH3-induced degradation was not analyzed. The 
acidic motif is present in both L- and KS-WNK1 isoforms. Thus, one 
might have expected that the missense mutations would have the 
same consequence on both isoforms. However, the 2 proteins have 
a different 3D structure, the conformation of which is probably 
regulated by different factors. Piala et al. showed that L-WNK1 is 
maintained in an inactive conformation by the binding of chloride 
to the catalytic site (39). KS-WNK1 is insensitive to this regulation 
because it lacks the major part of the kinase domain. Under physi-
ological conditions, KS-WNK1 mRNA is markedly more abundant 
than L-WNK1 in the distal nephron (13, 40), but data on KS-WNK1 
protein abundance are still lacking, since there are no specific anti-
bodies against this isoform. Our results obtained in both Xenopus 
oocytes and HEK293T cells suggest that KS-WNK1 protein could 
be physiologically degraded in the distal nephron by ubiquitination 
through the KLHL3-CUL3 E3 ligase complex.
The present study suggests that mutations in the WNK1 acidic 
motif drive altered potassium metabolism primarily by increasing 
KS-WNK1 abundance. The most parsimonious explanation for the 
phenotype is that the selective increase in KS-WNK1 abundance 
directly stimulates NCC activity and abrogates potassium-depen-
dent upregulation of ROMK. The explanation is consistent with 
recent observations indicating that KS-WNK1 is critical for the 
coalescence of WNK-SPAK signaling molecules into large mem-
braneless structures in the DCT, called WNK bodies (24), which 
appear to be key intermediates in WNK-SPAK phosphorylation 
of NCC, particularly during dietary potassium restriction (41). 
Because binding of KS-WNK1 to WNK4 increases the phosphory-
lation of the WNK4 T-loop (23) and the WNK bodies become larg-
er in DCT of Wnk1+/delE631 mice, we speculate that increased abun-
dance of KS-WNK1 in Wnk1+/delE631 mice drives phosphorylation 
of NCC through activation of the WNK4-SPAK cascade in WNK 
bodies. As evidenced by the rapid correction of hyperkalemia in 
Wnk1+/delE631 mice and patients with HCTZ, the aberrant activation 
of NCC most likely contributes to urinary potassium retention by 
reducing sodium delivery to ASDN.
The fact that an increased KS-WNK1 abundance stimulates 
NCC expression and phosphorylation in the Wnk1+/delE631 mice 
might be considered surprising, given that the same phenome-
non was observed in mice carrying an inactivation of KS-WNK1 
(KS-Wnk1–/– mice; ref. 42). However, given the information raised 
sic FHHt. Our cases are very similar to the 3 published cases of 
Spitzer-Weinstein syndrome, characterized by normotension and 
early onset hyperkalemic tubular acidosis and sensitive to HCTZ 
(34–36). The mutations are all located in the acidic motif, which 
is highly conserved across members of the WNK family and piv-
otal for their recruitment by KLHL proteins for ubiquitination by 
the CUL3-based E3 ligase ubiquitin complex (5, 37). Our in vitro 
experiments suggest that WNK1 mutations result in a differen-
tial regulation of the 2 major WNK1 isoforms, with an increase in 
abundance of KS-WNK1 being preferentially affected compared 
with the kinase-active L-WNK1.
Since the discovery that mutations in KLHL3 and CUL3 cause 
FHHt (3, 38), several studies have demonstrated that the WNK 
kinases are substrates for the KLHL3-CUL3 E3 ligase complex 
(37). Ohta et al. mapped the WNK interaction site to a region 
containing a motif of 10 amino acids, EPEEPEADQH, called the 
acidic motif because of the predominance of negatively charged 
residues (5). Most of the FHHt-causing mutations in WNK4 clus-
ter in this highly conserved motif (2). The analysis of the Kelch 
domain of KLHL3 crystal structure in complex with the WNK4 
acidic motif revealed close polar contacts between several resi-
dues at this motif and other conserved residues at the surface of 
the Kelch domain β-propeller (14). In particular, the D635 resi-
due of L-WNK1 (equivalent to D564 in WNK4) establishes ionic 
interactions with R528 of KLHL3, both residues being mutated 
in FHHt. Mutations in this degron motif abolish the interaction 
of WNK4 with the ubiquitin-ligase complex, thereby preventing 
their ubiquitination and proteasomal degradation. Accordingly, 
WNK4 protein abundance increases in the kidney of WNK4+/D561A 
mice, which carried 1 of the FHHt mutations (7, 39).
We found that KS-WNK1 abundance is much more affected by 
the acidic motif mutations than L-WNK1. While the expression of 
KLHL3 only slightly reduced L-WNK1 abundance, the expression 
of KS-WNK1 was drastically decreased in both X. laevis oocytes 
and mammalian cells (HEK293T). We also found that KS-WNK1 is 
more ubiquitinated than L-WNK1 when KLHL3 is overexpressed. 
Each of the mutations in the acidic motif abolished the degradation 
of KS-WNK1, with the exception of KS-WNK1 D228E. Ohta et al. 
previously demonstrated that L-WNK1 interacts with KLHL3 and 
that this interaction is prevented by mutations in either KLHL3 or 
the acidic motif of L-WNK1 (5). However, the effect of KLHL3 over-
expression on KS-WNK1 abundance and ubiquitination was not 
Table 3. BP and biological characteristics of the Wnk1+/delE631 mouse model
Basal HCTZ
Characteristics Wnk1+/+ Wnk1+/delE631 P value Wnk1+/+ Wnk1+/delE631 P value
SBP (mmHg) 110.3 ± 3.8 (n = 11) 119.0 ± 2.8 (n = 12) 0.07 108.4 ± 3.9 (n = 11) 114.3 ± 2.8 (n = 12) 0.02
Blood
Na+ (mmol/L) 144.8 ± 0.2 (n = 20) 145 ± 0.3 (n = 20) 0.61 144.5 ± 0.4 (n = 8) 143.3 ± 0.4 (n = 8) 0.05 (n = 8)
K+ (mmol/L) 4.4 ± 0.1 (n = 20) 5.1 ± 0.1 (n = 20)  < 0.0001 3.9 ± 0.1 (n = 8) 4.4 ± 0.1 (n = 8) 0.01
Cl– (mmol/L) 110.0 ± 0.6 (n = 20) 113.6 ± 0.4 (n = 20)  < 0.0001 106.8 ± 0.9 (n = 8) 106 ± 0.7 (n = 8) 0.53
Renin (units) 1.0 ± 0.2 (n = 7) 0.5 ± 0.1 (n = 7) 0.04 ND ND
Urine
Aldosterone (nmol/L) 6.8 ± 0.7 (n = 7) 11.5 ± 1.6 (n = 7) 0.02 ND ND
Aldo/creatinine (units) 1.5 ± 0.2 (n = 7) 2.5 ± 0.5 (n = 7) 0.09 ND ND
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that KS-WNK1 inhibits pathways that normally upregulate 
ROMK in the DCT2/CNT and this contributes to the potassi-
um-retention phenotype. This conclusion is consistent with 
observations in mice that KS-WNK1 gene ablation causes api-
cal membrane expression of ROMK to increase in the DCT2 
and CNT (42), but does not easily translate into an under-
standing of how KS-WNK1 physiologically regulates ROMK. 
However, recent patch-clamp studies in mice demonstrated 
that KS-WNK1 is necessary for the physiological stimulation 
of ROMK currents in response to a dietary potassium load 
(49), a condition known to stimulate KS-WNK1 transcrip-
tion (40). We speculate that KS-WNK1 may affect ROMK 
differently depending on the circumstance and where it is 
expressed. In Wnk1+/delE631 mice and patients, overexpressed 
KS-WNK1 in the DCT may indirectly inhibit ROMK in the 
CNT through distal nephron remodeling processes, as have 
been observed in a DCT-specific mouse model of FHHt (45). 
But when KS-WNK1 is physiologically activated in the CNT, 
its direct positive effects on ROMK would be completely 
opposite. Obviously, a test of these ideas will require further 
studies, perhaps with nephron-specific KS-WNK1 knockout 
and overexpression models.
The absence of hypertension in the patients and 
Wnk1+/delE631 mice is puzzling, given the increase in NCC 
phosphorylation. In that regard, it was interesting to compare 
the phenotypes of our FHHt patients depending on the WNK1 or 
WNK4 gene affected with similar genetic variants at the acidic 
motif of the kinase. Despite a relatively small number of affect-
ed subjects and difference in median age of the 2 groups (39.5 vs. 
23.0 years), it was clear that WNK4 patients had a much higher 
BP than those with similar mutations at the WNK1 gene (medi-
an 163/102 mmHg vs. 111/75 mmHg, respectively). In contrast, 
these 2 groups had a similar biological profile, characterized by 
marked hyperkalemia, hyperchloremia, and metabolic acido-
sis. In addition, the Wnk1+/delE631 mice are normotensive, even on 
a high–sodium chloride diet. Only homozygous mice displayed 
a higher basal SBP (Supplemental Table 5). These in vivo obser-
vations highly suggest a differential effect on NaCl reabsorption 
between the 2 genes, independent of NCC stimulation. Interest-
ingly, renin secretion was low in the patients with WNK1 muta-
tions at the acidic motif and renin transcription was reduced in 
Wnk1+/delE631 mice, as expected from the negative feedback loop of 
increased intravascular volume. However, ENaC expression was 
unchanged and natriuresis sensitivity to acute amiloride was not 
affected in mutant mice, suggesting that the hypertensive phe-
notype in FHHt may require increased ENaC activity. Finally, 
in the last 10 years, we now believe that increased NCC activity in 
KS-Wnk1–/– mice is not directly caused by KS-WNK1 inactivation, 
but is rather the consequence of the potassium-losing phenotype. 
The latter could be caused by the increased ROMK expression 
observed in the DCT2/CNT of these mice and associated with 
a decrease in aldosterone secretion in the absence of decreased 
renin expression (our unpublished observations). This new inter-
pretation is supported by the fact that all the other mouse models 
in which NCC is stimulated display hypertension and hyperkale-
mia (Wnk4-PHAII transgenic mice ref. 19; WNK4D561A/+ knockin 
mice, ref. 18; KLHL3–/– mice, ref. 43, KLHL3R582/+ mice, ref. 44, and 
constitutively active SPAK mutant mice, ref. 45). In addition, our 
original interpretation of the phenotype resulting from KS-WNK1 
inactivation (42) was guided by the early oocyte studies, which 
suggested that this WNK1 isoform exerted a dominant nega-
tive effect on L-WNK1 (46). However, we have since shown that 
an unfortunate mutation in the L- and KS-WNK1 cDNA used in 
these oocyte studies caused spurious loss of function (47). A new-
er study in oocytes, using the corrected cDNA, now indicates that 
KS-WNK1 in an activator of WNK4 (48).
Based on our observation that Wnk1+/delE631 mice fail to proper-
ly upregulate ROMK in the setting of hyperkalemia, it seems likely 
Figure 6. Activation of the SPAK-NCC phosphorylation cascade in 
Wnk1+/delE631 mice. (A) Representative immunoblots with the indi-
cated antibodies performed on the membrane-enriched fractions 
(NCC and pNCC) or total homogenates of the renal cortex of mice 
of each genotype. (B) Densitometric analysis. NCC, SPAK, and OSR1 
abundance and phosphorylation are increased in Wnk1+/delE631 mice 
compared with Wnk1+/+ mice. WNK4 expression is similar between 
the 2 groups of mice. The expression level in Wnk1+/+ mice was 
arbitrarily set to 100. Data are represented as mean ± SEM.  
***P < 0.001 ; **** P < 0.0001, unpaired Student’s t test.
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ian robust linear model with Mahalanobis distance classifier 
(BRLMM) and only analyzed SNPs with BRLMM = 0.15. We 
applied the 1 Mb to 1 centimorgan conversion before analysis 
as recommended (50). Checks for Mendelian errors and para-
metric linkage analyses were computed by MERLIN (51) under 
a rare dominant model with full penetrance (100%) and a dis-
ease allele frequency of 0.0005.
WES. IntegraGen performed library preparation, cap-
ture, sequencing, and variant detection and annotation. 
Exons of genomic DNA samples were captured using Agilent 
in-solution enrichment methodology with their biotinylated 
oligonucleotides probes library, followed by paired-end 75 bp 
massively parallel sequencing on Illumina HiSeq 2000 (see 
ref. 52 for detailed explanation of the process). The bioinfo-
matics analysis of deep-sequencing data was based on the 
Illumina pipeline (CASAVA 1.8).
Direct Sanger sequencing
PCR amplification and Sanger sequencing from genomic DNA 
was performed using standard methods. The sequencing of the 
WNK1 ex7 and ex25 was performed using the primers listed in 
Supplemental Table 7A.
In vitro functional characterization
Mutant proteins in X. laevis oocytes. Vectors used for expression in 
Xenopus oocytes and HEK293 cells are described in the Supplemen-
tal Methods. cRNA for Xenopus oocyte injections were prepared by in 
vitro transcription of the corresponding human clones after plasmid 
linearization using the T7 RNA polymerase m MESSAGE kit (Ambion).
We used X. laevis oocytes as an expression system. Oocyte prepa-
ration protocol has been described before (53). In brief, oocytes were 
obtained from female frogs under anesthesia and the follicular lay-
er was removed. After 24 hours, oocytes were injected with 50 nL 
of H2O alone or containing 0.2 μg/μl of each clone cRNA. After 48 
hours of incubation, protein extracts were obtained using lysis buf-
fer containing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 
50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 1% (wt/vol) Nonidet P-40, 0.27 M sucrose, 0.1% (vol/
vol) 2-mercaptoethanol, and protease inhibitors (Complete Tablets; 
Roche). Protein extracts equivalent to 1 oocyte (60 μg) were resolved 
using SDS-PAGE and transferred to PVDF membranes for Western 
blot analysis. The antibodies used were commercial c-myc (catalog 
11814150001, Roche/MilliporeSigma) and Flag antibody (M2, catalog 
A6592; MilliporeSigma) at 1:1000 and 1:5000 as well as commer-
cial anti–β-actin (catalog sc47778; Santa-Cruz Biotechnology Inc.) at 
1:2500. Immobilized antigens were detected by chemiluminesence 
using the Luminata Forte Western HRP substrate (Merck Millipore).
BP remained lower in Wnk1+/delE631 mice fed a low K+ diet compared 
with WT littermates, demonstrating that the hyperkalemia was not 
responsible for the renin inhibition. Taken together, these results 
suggest that Wnk1+/delE631 mice and the patients display a mild hyper-
volemic state and that the full understanding of the mechanisms 
underlying the absence of hypertension remain to be identified.
In conclusion, the discovery of mutations within the WNK1 
acidic motif and their in vitro and in vivo characterization uncov-
er what we believe are new features of the KS-WNK1 isoform. We 
found that KS-WNK1 acts as a positive modulator of NCC that is 
preferentially degraded at the protein level by the KLHL3-CUL3 
ubiquitin complex compared with the L-WNK1 isoform. In the 
pathological conditions observed here, mutations in the acid-
ic motif prevent KLHL3-CUL3 interaction, leading to increased 




Linkage analysis. Linkage in Ped29 was analyzed using markers gener-
ated by the 250K Affymetrix array, as previously performed (38). We 
excluded nonpolymorphic and low-frequency (minor allele frequency 
[MAF] < 0.1) SNPs. To decrease the SNPs list to a manageable set of 
49,187 SNPs for linkage analysis, we applied a filter using the Bayes-
Figure 7. The DCTs of Wnk1+/delE631 mice contain large WNK 
bodies. (A) Immunofluorescence experiments using WNK1 and 
NCC antibodies. While only small puncta are observed in Wnk1+/+ 
DCT, large WNK1-positive structures are found in Wnk1+/delE631 
DCT, resembling the previously described WNK bodies. Scale bar: 
10 μm. (B) Costaining with NCC, AQP2, and NKCC2 revealed that 
these bodies are localized in the DCT and CNT/CCD, but not in 
Henle’s loop. Scale bar: 20 μm.
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Figure 8. Abnormal K+ handling in Wnk1+/delE631 mice. (A–C) Decreased UK+ excretion, Uk/Pk ratio, and TTKG. (A) Urinary K+ excretion was lower in Wnk1+/delE631  
(n = 7, 52 ± 5.3 mmol/mmol creatinine) than in Wnk1+/+ mice (n = 7, 69.3 ± 7.9 mmol/mmol creatinine). *P < 0.05, unpaired Student’s t test. (B) Basal 
urinary/plasma ratio of K+ concentration was lower in Wnk1+/delE631 (n = 24, 37.2 ± 2.1) than in Wnk1+/+ mice (n = 24, 56.3 ± 3.8). ***P < 0.0001, unpaired 
Student’s t test. (C) TTKG was significantly lower in Wnk1+/delE631 (n = 24, 8.6 ± 0.3) than in Wnk1+/+ mice (n = 24, 10.1 ± 0.3). ***P = 0.0003. Following 
4-day HCTZ oral (240 mg/kg/d) administration, the difference in TTKG between Wnk1+/+ and Wnk1+/delE631 remained the same (9.5 ±0.9 versus 11.8 ±0.8, 
respectively) although no more significant (P = 0.068), likely because of the smaller number of animals studied (n = 9 and n = 11, respectively). Statisti-
cal comparisons were made using unpaired t tests. (D) ENaC expression. Representative immunoblots with the indicated antibodies performed on the 
membrane-enriched fractions of the renal cortex of mice of each genotype. Densitometric analysis. The abundance of the cleaved form of the α-subunit 
of ENaC was significantly increased in Wnk1+/delE631 mice compared with Wnk1+/+ mice. The expression level in Wnk1+/+ mice was arbitrarily set to 100. Data 
are represented as mean ± SEM.*P < 0.05, unpaired Student’s t test. (E and F) Natriuretic and kaliuretic response to amiloride. Urinary Na+ (E) and K+ (F) 
excretion in response to amiloride injection. Wnk1+/+ and Wnk1+/delE631 males (n = 7 in each group) were housed in metabolic cages and received 1 injection of 
vehicle or amiloride on 2 consecutive days. Urine was collected 6 hours after injection. Data are represented as mean ± SEM. *P < 0.05; **P< 0.01;  
****P < 0.0001 versus vehicle, unpaired Student’s t test.
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were transiently transfected using Effectene (QIAGEN) following the 
manufacturer’s instructions.
Immunoprecipitation. Cells were harvested 48 hours after trans-
fection, washed in cold PBS, and frozen in liquid nitrogen. Lysis/
immunoprecipitation of cell pellets in denaturing or native condi-
tions were performed according to classical procedures described in 
Supplemental Methods.
Mutant proteins in HEK293T cells
Cell culture and transfection. Flp-InTM T-RExTM 293 cells (Invit-
rogen) were stably transfected with pCDNA5/FRT/(His)6-protein 
C-Flag-hKLHL3 WT or R528H vector following the manufacturer’s 
instructions. Conditions of culture and induction are described in Sup-
plemental Methods. For expression of WNK1-myc constructs (pcDNA 
vectors described in Supplemental Methods) and ubiquitin-HA, cells 
Figure 9. Expression of ROMK, BK channel, and NKCC2. (A) ROMK protein abundance. No change in cortical ROMK expression was observed in Wnk1+/delE631 
(n = 4) vs. littermate Wnk1+/+ (n = 4) mice, despite the latter group having significantly higher plasma K+ levels (4.4 ± 0.08 mM, n = 20 vs. 5.1 ± 0.12 mM,  
n = 20). Conversely, a more than 2-fold increase was observed in Wnk1+/+ mice treated by amiloride (25 mg/kg/d for 4 days) achieving a similar rise in plas-
ma potassium (Wnk1+/+ vehicle: 3.8 ± 0.06 mM, n = 4 vs. Wnk1+/+ amiloride: 5.0 ± 0.11 mM). Quantification of cortical ROMK expression (n = 4 per group).  
*P < 0.05, t test. (B) ROMK immunofluorescence in the distal tubule. Left panel: immunolocalization of ROMK in the DCT2 of Wnk1+/+ and Wnk1+/delE631 
mice. Right panel: analysis of membrane labeling intensity showed no change in ROMK apical expression in the DCT2 and CNT of Wnk1+/delE631 mice (n = 4 
animals per genotype). Scale bar: 10 microns. (C) Basal BK α channel protein abundance in Wnk1+/delE631 mice and Wnk1+/+ littermates. BK α immunoblots 
(left panel) and quantification (right panel) demonstrate that cortical BK α expression is unchanged between Wnk1+/+ (n = 4) and Wnk1+/delE631 mice (n = 5). 
(D) Basal NKCC2 and P-NKCC2 protein abundance in Wnk1+/delE631 mice and Wnk1+/+ littermates. (n = 7 per group). NKCC2 and pNKCC2 immunoblots (left 
panel) and quantification (right panel) demonstrate that NKCC expression is unchanged between Wnk1+/+ (n = 7) and Wnk1+/delE631 mice (n = 7), but pNKCC2 
is significantly increased in Wnk1+/delE631 mice compared with Wnk1+/+. ****P < 0.0001, unpaired Student’s t test.
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Blood and urine measurements. Plasma electrolytes were measured 
using an i-STAT system (Abbott) and EC-8+ cartridge test. Blood sam-
ples were collected under isoflurane anesthesia by retroorbital punc-
ture. Creatinine was determined using an Olympus AU400 analyzer. 
Urinary aldosterone was measured by competitive chemiluminescent 
immunoassay (LIAISON Aldosterone Kit, Diasorin). TTKG was cal-
culated as follows (26): TTKG = ([K+]urine/[K+]blood) × (osmblood/
osmurine), as has been used widely before in animal model studies 
to estimate the potassium secretory capacity of the distal nephron. 
Although urea recycling has been argued as making TTKG greater 
than the actual value in vivo (55), the error is small (~10%) because the 
urea reabsorption is offset by passive potassium reabsorption in the 
inner medullary collecting duct (56). This is in agreement with exper-
imental measurements that have validated the TTKG calculation as a 
reasonable estimate of potassium secretory capacity in rodents (57). 
Although we cannot rule out that urea recycling or passive potassium 
reabsorption is affected by the WNK1 ex7 mutation, it seems unlikely. 
Nevertheless, we acknowledge this as a limitation.
RNA extraction and RT-qPCR for renin expression. The extraction of 
total RNA from mouse kidneys, reverse transcription and quantitative 
PCR (RT-qPCR) were performed as described in ref. 12. Primer sequenc-
es are indicated in Supplemental Table 7D. Ubiquitin c (ubc) was used 
a reference gene, and comparative quantification of the gene of interest 
between the 2 genotypes was obtained using the 2−ΔΔCt method. 
Mouse kidney immunoblotting. At the end of the experimental 
period, animals were sacrificed with ketamine and xylazine (0.1 and 
0.01 mg/g of body weight, respectively). Renal cortex or total renal 
samples were homogenized, extracted, and submitted to SDS-PAGE 
electrophoresis, and immunoblotting was performed as detailed in 
Supplemental Methods.
WNK1 and ROMK1 immunolocalization in the cortical nephron. 
WNK1 and ROMK1 immunofluorescence experiments were per-
formed on kidneys embedded in paraffin. All technical details are giv-
en in Supplemental Methods.
Statistics
Human studies. Data were analyzed using Fisher’s exact and t tests. All 
tests were 2 sided. P values of less than 0.05 were considered significant.
Mouse studies. When analyzing 2 groups of mice, we used an unpaired 
Student’s t test. One-way ANOVA followed by Holm-Šidák’s multiple 
comparisons test was used to analyze more than 2 groups of 5 or more 
while a Kruskal-Wallis test followed by a Mann-Whitney U test was used 
to analyze more than 2 groups of 5 or less. Data are given as mean ± SEM. 
Differences between groups were considered significant at P < 0.05.
Study approval
Affected individuals were recruited at the Department of Genetics of 
the Hôpital Européen Georges Pompidou as well as at other Depart-
ments of Nephrology located in France, Italy, and the United King-
dom. Genetic testing and research were performed according to the 
French ethic laws published in 2001 (articles L.1110-4 al 1 CSP and R 
1131-14 CSP). Informed, written consent was obtained from all study 
participants. All mouse studies were conducted on 3- to 5-month-old 
male mice and performed in accordance with the European Commu-
nities Council Directive. The project was approved by the French Min-
istry of Research (no. 02650.02). Work with X. laevis was approved 
and performed following the guidelines set by the Institutional Animal 
Immunoblotting. Lysates and immunoprecipitates were ana-
lyzed by SDS-PAGE (6% or 8% gels), transferred to nitrocellulose 
membrane, and immunoblotted with primary antibodies including 
anti-HA (Cell Signaling Technology), anti-myc (clone 9B11, Cell 
Signaling Technology), anti-protein C (clone hpc4, Roche), rabbit 
anti-GAPDH (catalog ab37168; Abcam), and goat anti-actin (cata-
log sc47778; Santa Cruz Biotechnology Inc.). Thereafter, the mem-
branes were incubated with a horseradish peroxidase–conjugated 
secondary antibody (1:5000 dilution). Images were obtained with 
chemiluminescence (Pierce ECL Western Blotting Substrate) using a 
luminescent image analyzer (LAS-4000 mini, Fujifilm) and quanti-
fied with MultiGauge software.
Mouse experimental studies
Crispr/Cas9 engineered mice. In order to produce the c.1905T>A, 
P.D635E mutation at ex7 of the mouse Wnk1 gene using the CRISPR/
Cas9 system, we chose three 20 mer sgRNAs (Supplemental Table 
7C), using the CRISPR Design algorithm (http://zlab.bio/guide- 
design-resources). sgRNAs were produced with Cas9 SmartNuclease 
RNA System (SBI Ozyme), and quality was controlled by the Experion 
Automated Electrophoresis System (Bio-Rad).
One-cell zygotes (3 series of 100 oocytes) were coinjected with 
CAS9WT protein (New England Biolabs), 1 of the 3 sgRNAs, and a 
single-strand 160 mer nucleotide (ssODN) carrying the acidic motif 
mutation and 80 bases of flanking sequence on each side of the cut 
(ref. 54 and Supplemental Table 7C). This ssODN has been designed 
to achieve high HDR efficiency; sgRNA/CAS9 system efficiency was 
validated in vitro by PCR digestion. About 10% of injected zygotes (30 
blastocysts) were amplified by PCR (primers in Supplemental Table 
7C) and analyzed by high-resolution melting (HRM), droplet digital 
PCR (ddPCR) (Bio-Rad), and sequencing to identify indel or muta-
tions. After birth, mouse biopsies were analyzed by sequencing.
Radiotelemetry monitoring of BP and heart rate. The study was per-
formed on 14 C57BL6J male mice divided in 2 subgroups (7 control 
Wnk1+/+, 7 Wnk1+/delE631 mice). Mice were implanted with BP and heart-
rate measuring telemetric probes (DSI). The precise monitoring of the 
animals is described in Supplemental Methods.
Basal conditions. Animals were housed in metabolic cages and fed 
a standard diet (0.3% NaCl) with free access to tap water. After a 3-day 
adaptation period, urine was collected daily for electrolyte measure-
ments for 2 days.
Diets. The standard diet contained 0.3% NaCl and 1% KCl; low K 
diet contained 0.3% NaCl and 0% KCl; high-salt diet contained 3% 
NaCl and 1% KCl.
Amiloride. After a 3-day adaptation period, physiological saline 
was injected intraperitoneally at 10:00 am and urine was collected 
6 hours after the injection. The same procedure was repeated the 
day after with an injection of amiloride (1.45 mg/kg body weight) 
dissolved in physiological saline. For the analysis of the variations in 
physiological ROMK expression response to blood potassium increase 
as well as for the measurement of TTKG, amiloride was administered 
intraperitoneally at the same dose over 4 days.
HCTZ. Animals were fed with a specific diet supplemented with 
HCTZ (240 mg/kg/d, oral) over 4 to 7 days such as done in previous stud-
ies (13, 19) for analysis of BP response and analysis of TTKG variations.
Metolazone. Metolazone (50 μg/kg/d) was administered intraper-
itoneally over 4 days.
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